Panacea Biotec in pink of health after launching vaccine

Panacea Biotec rose 4.68% to Rs 161.16 at 14:00 IST on BSE after the company introduced world's first fully liquid whole cell pertussis hexavalent combination vaccine EasySix for six preventable diseases.

The announcement was made during market hours today, 29 March 2017.

Meanwhile, the S&P BSE Sensex was up 105.96 points, or 0.36% to 29,515.48. The S&P BSE Small-Cap index was up 60.44 points or 0.43% to 14,213.81.

On the BSE, 39,933 shares were traded in the counter so far, compared with average daily volumes of 47,302 shares in the past one quarter. The stock had hit a high of Rs 167.80 and a low of Rs 153.05 so far during the day. The stock had hit a 52-week high of Rs 178.30 on 27 January 2017. The stock had hit a 52-week low of Rs 85.50 on 26 May 2016.

The small-cap company has equity capital of Rs 6.13 crore. Face value per share is Re 1.

Panacea Biotec said the vaccine was researched, developed and manufactured by the company in India. EasySix is indicated for primary immunization to protect newborn babies against six preventive diseases namely, Diptheria, Tetanus, Whopping Cough, Hepatitis B and Polio.

Panacea Biotec reported net loss of Rs 29.25 crore in Q3 December 2016, higher than net loss of Rs 17.38 crore in Q3 December 2015. Net sales declined 34% to Rs 99.33 crore in Q3 December 2016 over Q3 December 2015.

Panacea Biotec is one of India's leading research based biotechnology companies with established research, manufacturing and marketing capabilities.

Powered by Capital Market - Live News